ClinicaliQ Trial Snapshot
- Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study) — Recruiting • Cardiology / Cardiovascular • NCT07772570.
- What is being tested: The study investigates multiple biomarkers (biological markers) to understand how coronary artery disease develops and progresses, particularly in patients experiencing acute myocardial infarction, aiming to identify new predictive and diagnostic indicators of disease pathogenesis.
- Patient eligibility overview: The trial enrolls patients presenting with acute myocardial infarction (heart attack) and likely includes individuals with established or suspected coronary artery disease, with specific inclusion/exclusion criteria determining participation based on clinical presentation and disease status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle. Although much has been learned about coronary artery…
Eligibility Snapshot
- : * Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.